# How Eli Lilly and Company (LLY) compares with the whole market and its popular alternatives

> Source: EasyCompare research, https://easycompare.io/research/lly
> Data as of October 20, 2026. Total returns include reinvested dividends. Past performance does not predict future results; nothing here is investment advice.

Built by QuantCommons' quantitative engine, this page is about relative opportunity, not data on LLY alone. It places LLY (Eli Lilly and Company) against 20+ popular alternatives, its neighboring categories and the entire market of over 10,000 U.S.-listed stocks and ETFs, and surfaces what has done better on consistent outperformance, return for the risk taken, behavior in real market crashes and diversification. The result is a clearer view of where LLY stands in the market, and of the alternatives worth a closer look.

Period covered: LLY's full trading record, from October 1986 through September 2026. All returns include reinvested dividends. Data as of October 20, 2026.

## Key findings

- **Right now:** Over the past 6 months, LLY rose 40.0% against 9.1% for the S&P 500 and 11.2% for the Nasdaq 100. LLY has bounced back 52.6% from its August 2025 low after a 34.5% loss from August 2024 to August 2025 over the same months the S&P 500 rose 14.4%.
- **Stock or market?:** More than an industry move: LLY rose 12.1% over the past 3 months, against 5.0% for the pharmaceuticals ETF IHE (iShares U.S. Pharmaceuticals ETF). The S&P 500 rose 3.9%. Last month cut against the tape: LLY rose 10.2% while the S&P 500 fell 0.6%.
- **Past 1 to 3 years:** Over the past year, LLY rose 59.7% against 15.8% for the S&P 500 and 17.9% for the Nasdaq 100. The same gap shows up over 3 years (124% against 89.3%). LLY finished ahead of the S&P 500 in both 2024 and 2025.
- **Long term:** LLY turned $10,000 into $191,000 over the past decade, against $42,100 in the S&P 500. LLY's 10-year return of 1,807% puts it ahead of 98% of the stocks worth at least $300 million with that much history. The S&P 500 returned 321%.
- **In a crash:** LLY fell less than the S&P 500 in five of seven sell-offs, but the 2015 China and oil sell-off broke the pattern: it fell 19.6%, more than the S&P 500's 12.8%.
- **Diversification:** Against the S&P 500, LLY has a correlation of 0.22 over 5 years, less closely than 82% of stocks worth at least $300 million. Next to an index fund it is a real diversifier. Over 10 years, LLY's beta versus the S&P 500 was 0.37: in the S&P 500's rising months it gained 1.0 times as much as the index, and in falling months it lost 6% as much.
- **Better options**
  - **Nearby categories and themes:** CAH (Cardinal Health, health care distribution) earned more than LLY with less volatility over the past 5 years: 42.1% a year at 24.7% volatility, against 40.7% a year at 32.8%.
  - **Whole market:** Few investments have done better on both counts: only one of the 3,633 stocks and funds worth at least $500 million earned more than LLY with less volatility over the past 5 years, among them CAH (Cardinal Health).

## How much would $10,000 in LLY have grown?

This chart tracks a hypothetical $10,000 investment in LLY over the past 29 years, with dividends reinvested, alongside the same amount in the S&P 500, investments that ended ahead of LLY over the same span and LLY's popular alternatives, among those that traded for the entire period.

- $10,000 invested in LLY at the end of September 1997 would have grown to $396,376 by September 2026, more than the $132,907 it would have become in SPY, an S&P 500 fund.
- Five of the eight other investments on the chart ended ahead of LLY, and GILD finished highest, at $1,571,438.

## LLY at a glance

This section summarizes the key facts about the stock, its returns over periods from one to ten years and the risk it has carried, with dividends reinvested throughout.

- LLY's deepest decline since it began trading in 1986 was 68.3%, from August 2000 to March 2009. It took about six years from the low to climb back to its old high.
- LLY is trading within 1% of its all-time high.
- Over 29 full calendar years, LLY's best was 1997, when it returned 93.6%, and its worst was 1999, when it lost 24.3%. It lost money in eight of those years.

- Type: Stock, Healthcare (Drug Manufacturers - General)
- Trading since: October 17, 1986
- Market value: $1.2T
- Volatility (5 years): 32.8%; Sharpe ratio: 1.21
- Worst decline ever: −68.3%, from August 8, 2000 to March 5, 2009; back at its high by November 4, 2014

| Period | LLY total return |
| --- | --- |
| 1 month | +10.2% |
| 3 months | +12.1% |
| 6 months | +40.0% |
| year to date | +19.4% |
| 1 year | +59.7% |
| 3 years | +124% |
| 5 years | +451% |
| 10 years | +1,807% |

## LLY against the whole market

Where LLY ranks among every stock and fund, and what across the market has done better.

### How does LLY rank among all stocks?

This section ranks LLY on return, volatility, risk-adjusted return and worst decline against every stock worth at least $300 million with enough history.

- On return for the risk taken (the Sharpe ratio), LLY ranks in the top 1% of the 2,893 stocks worth at least $300 million.

| Measure | LLY | Rank |
| --- | --- | --- |
| 1-year return | +59.7% | 423 of 3,287 (top 13%) |
| 3-year return | +124% | 742 of 3,017 (top 25%) |
| 5-year return | +451% | 77 of 2,893 (top 3%) |
| 10-year return | +1,807% | 46 of 2,202 (top 3%) |
| Volatility, 5 years | 32.8% | 979 of 2,893 (top 34%) |
| Sharpe ratio, 5 years | 1.21 | 21 of 2,893 (top 1%) |
| Worst decline, past 10 years | −34.5% | 64 of 2,187 (top 3%) |

### What has beaten LLY on both return and risk?

Each dot is an investment, placed by how much it earned a year over the past 5 years (higher is better) and how much its price swung, its volatility (further left is calmer).

- One stock worth at least $500 million sit in the green region: each earned more than LLY over the past 5 years with smaller price swings. That is fewer than 1% of the 3,633 screened. Few investments beat it on both counts.
- Among those with at least half LLY's swings, CAH has the best return for its risk: 42.1% a year at 24.7% volatility, 25% less than LLY's 32.8%, and a Sharpe ratio (return above cash per unit of volatility) of 1.55 against 1.21 for LLY.
- None of LLY's popular alternatives made it, but CAH (health care distribution) did: 42.1% a year at 24.7% volatility, 25% less than LLY's 32.8%.

### Is there a better investment than LLY?

The table below lists investments that beat LLY over the past 5 years on at least one of these measures: a higher annual return with lower volatility, a higher annual return at similar volatility, a similar return with lower volatility, a higher Sharpe ratio with a smaller worst decline, a higher total return in most periods from 3 months to 10 years, or smaller losses in recent market crashes.

- Looking beyond its popular alternatives, CAH (health care distribution) earned more than LLY with less volatility over the past 5 years: 42.1% a year at 24.7% volatility, against 40.7% a year at 32.8%.
- Few investments have done better on both counts: only one of the 3,633 stocks and funds worth at least $500 million earned more than LLY with less volatility over the past 5 years, among them CAH.

The 1 strongest of 1 investments that beat LLY over the past 5 years, out of 3,633 stocks and funds worth at least $500 million.

| Investment | Group | Annual return (5 years) | Volatility | Sharpe | Worst decline (10 years) | 10Y return | Correlation with LLY | Better on |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| LLY: Eli Lilly and Company (this page) |  | +40.7% | 32.8% | 1.21 | −34.5% | +1,807% |  |  |
| [CAH](https://easycompare.io/research/cah): Cardinal Health, Inc. | Health Care Distribution | +42.1% | 24.7% | 1.55 | −46.1% | +349% | 0.28 | Higher return, lower volatility; Higher return in most periods |

## LLY against its popular alternatives

The investments people most often weigh against LLY, compared period by period and year by year.

### How do LLY's risk and return compare with its alternatives?

This map plots each investment's annual return over the past 5 years against its volatility, the size of its typical price swings.

- None of the 22 popular alternatives earned more than LLY over the past 5 years with smaller price swings, so every higher return on the map came with a bumpier ride.
- Over the past 5 years, LLY returned 40.7% a year, more than the S&P 500's 12.7%, with higher volatility (32.8% against 17.1%).

### Has LLY consistently beaten its popular alternatives?

This section compares LLY with the investments people most often weigh against it, checking each one over eight periods from one month to ten years.

- None of the 22 popular alternatives outperformed LLY in at least 3 of 5 short-term and 2 of 3 long-term timeframes. The closest was VKTX.

| Investment | 1Y return | 3Y return | 5Y return | 10Y return | Periods ahead of LLY | Verdict | Sharpe |
| --- | --- | --- | --- | --- | --- | --- | --- |
| LLY: Eli Lilly and Company (this page) | +59.7% | +124% | +451% | +1,807% |  |  | 1.21 |
| VKTX: Viking Therapeutics, Inc. | −20.9% | +166% | +360% | +2,223% | 0/5 short-term, 2/3 long-term |  | 0.72 |
| BIIB: Biogen Inc. | +65.8% | −5.6% | −8.8% | −18.9% | 4/5 short-term, 0/3 long-term |  | 0.11 |
| [ABBV](https://easycompare.io/research/abbv): AbbVie Inc. | +28.3% | +118% | +218% | +603% | 3/5 short-term, 0/3 long-term |  | 1.11 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | +48.7% | +72.2% | +145% | +266% | 3/5 short-term, 0/3 long-term |  | 0.85 |
| [MRK](https://easycompare.io/research/mrk): Merck & Co., Inc. | +76.8% | +58.3% | +113% | +241% | 3/5 short-term, 0/3 long-term |  | 0.74 |
| DXCM: DexCom, Inc. | +25.3% | −0.3% | −38.4% | +316% | 2/5 short-term, 0/3 long-term |  | 0.04 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | +30.3% | +121% | +180% | +200% | 2/5 short-term, 0/3 long-term |  | 0.95 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | +30.5% | +19.2% | −8.3% | +55.0% | 2/5 short-term, 0/3 long-term |  | 0.06 |
| [TAK](https://easycompare.io/research/tak): Takeda Pharmaceutical Company Limited | +48.2% | +56.1% | +75.1% | +30.4% | 2/5 short-term, 0/3 long-term |  | 0.68 |
| VTRS: Viatris Inc. | +87.1% | +127% | +64.3% | −38.0% | 2/5 short-term, 0/3 long-term |  | 0.47 |
| WST: West Pharmaceutical Services, Inc. | +41.9% | +7.8% | −5.0% | +455% | 1/5 short-term, 0/3 long-term |  | 0.19 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | +26.8% | +49.5% | +15.1% | +366% | 1/5 short-term, 0/3 long-term |  | 0.24 |
| [JNJ](https://easycompare.io/research/jnj): Johnson & Johnson | +36.9% | +84.6% | +82.1% | +196% | 1/5 short-term, 0/3 long-term |  | 0.76 |
| [REGN](https://easycompare.io/research/regn): Regeneron Pharmaceuticals, Inc. | +40.7% | +0.8% | +44.9% | +120% | 1/5 short-term, 0/3 long-term |  | 0.40 |
| [VRTX](https://easycompare.io/research/vrtx): Vertex Pharmaceuticals Incorporated | +22.8% | +42.2% | +177% | +521% | 0/5 short-term, 0/3 long-term |  | 0.85 |
| [AZN](https://easycompare.io/research/azn): AstraZeneca PLC | +1.8% | +38.8% | +52.1% | +257% | 0/5 short-term, 0/3 long-term |  | 0.41 |
| PODD: Insulet Corp. | −56.4% | −1.4% | −52.2% | +255% | 0/5 short-term, 0/3 long-term |  | -0.12 |
| [NVS](https://easycompare.io/research/nvs): Novartis AG | +18.8% | +75.9% | +121% | +226% | 0/5 short-term, 0/3 long-term |  | 0.87 |
| [NVO](https://easycompare.io/research/nvo): Novo Nordisk A/S | −28.5% | −57.0% | −18.5% | +134% | 0/5 short-term, 0/3 long-term |  | 0.09 |
| [GSK](https://easycompare.io/research/gsk): GSK plc | +18.9% | +60.0% | +57.2% | +95.1% | 0/5 short-term, 0/3 long-term |  | 0.49 |
| [BMY](https://easycompare.io/research/bmy): Bristol-Myers Squibb Company | +47.8% | +25.8% | +30.6% | +74.8% | 0/5 short-term, 0/3 long-term |  | 0.34 |
| [SNY](https://easycompare.io/research/sny): Sanofi | −13.4% | −10.0% | +3.0% | +61.5% | 0/5 short-term, 0/3 long-term |  | 0.15 |

### How did LLY do year by year?

This table shows each investment's total return in every full calendar year since 1997, along with where LLY ranked among its popular alternatives each year.

- LLY finished ahead of the S&P 500 in 16 of its 29 full calendar years, and ahead of it in each of the last six.
- Ranked against its popular alternatives each year, LLY finished in the top quarter in 11 of 29 years and in the bottom quarter in four. In 2025, it ranked 4 of 23.
- Among its popular alternatives, TMO came out ahead of LLY most often, in 16 of the 29 years both traded.

| Year | LLY | SPY |
| --- | --- | --- |
| 2025 | +40.3% | +17.7% |
| 2024 | +33.3% | +24.9% |
| 2023 | +60.9% | +26.2% |
| 2022 | +34.3% | −18.2% |
| 2021 | +66.1% | +28.7% |
| 2020 | +31.0% | +18.3% |
| 2019 | +16.2% | +31.2% |
| 2018 | +40.5% | −4.6% |
| 2017 | +17.8% | +21.7% |
| 2016 | −10.4% | +12.0% |

## Risk and diversification

How LLY has fallen, how it held up in crashes beside the S&P 500 and its popular alternatives, and what moves independently of it.

### What were LLY's worst declines?

A drawdown is the decline from a peak to the lowest point before a new high.

- In all three of LLY's worst declines, the S&P 500 held up better over the same dates.
- Not every decline was the market's doing: LLY fell 43.3% from March 1999 to March 2000, while the S&P 500 rose 8.6%.
- The slowest recovery came after LLY fell 68.3% from August 2000 to March 2009; it did not regain that peak until November 2014, six years later.

| Decline | Peak | Low | Back at the high | SPY over the same dates | Market event |
| --- | --- | --- | --- | --- | --- |
| −68.3% | August 8, 2000 | March 5, 2009 | November 4, 2014 | −46.4% | dot-com bust |
| −46.4% | January 9, 1992 | August 13, 1993 | March 27, 1995 | — |  |
| −43.3% | March 5, 1999 | March 7, 2000 | June 29, 2000 | +8.6% |  |
| −40.8% | September 14, 1987 | October 19, 1987 | March 13, 1989 | — |  |
| −34.5% | August 30, 2024 | August 8, 2025 | November 10, 2025 | +14.4% |  |

### How did LLY do in stock market crashes?

This section measures how far LLY, the S&P 500 and each alternative fell from peak to trough during every major market crash since 2000.

- LLY fell less than the S&P 500 in seven of the ten crashes it has traded through. The clearest case was the Covid crash, when LLY fell 16.9% and the S&P 500 fell 33.7%.
- None of its popular alternatives fell less than LLY in most of the crashes they both traded through.

| Crash | Dates | LLY fall | SPY fall |
| --- | --- | --- | --- |
| Dot-com bust | March 10, 2000 to October 9, 2002 | −54.3% | −47.5% |
| Global financial crisis | October 9, 2007 to March 9, 2009 | −50.0% | −55.2% |
| Flash crash | May 6, 2010 to May 7, 2010 | 0.0% | −1.5% |
| Euro debt crisis | July 22, 2011 to October 3, 2011 | −10.9% | −17.9% |
| China devaluation & oil rout | August 10, 2015 to February 11, 2016 | −19.6% | −12.8% |
| Volmageddon | February 2, 2018 to February 9, 2018 | −8.6% | −6.5% |
| Q4 2018 selloff | September 21, 2018 to December 24, 2018 | −10.2% | −19.3% |
| COVID crash | February 19, 2020 to March 23, 2020 | −16.9% | −33.7% |
| 2022 bear market | January 4, 2022 to October 12, 2022 | −11.7% | −24.5% |
| SVB / regional bank stress | March 8, 2023 to March 13, 2023 | −0.6% | −3.4% |

### How closely does LLY move with the S&P 500?

Upside capture measures how much of the S&P 500's gains an investment kept in the months the market rose, and downside capture how much of its losses it took in the months the market fell.

- None of the 22 popular alternatives with the same record had a higher capture ratio (upside capture divided by downside capture) than LLY's 15.73.
- Over the past 10 years, LLY captured 101% of the S&P 500's gains in rising months and 6% of its losses in falling months, with a beta of 0.37. Its share of the market's gains was larger than its share of the losses.

Measured over the past 10 years of monthly returns against SPY.

| Investment | Upside capture | Downside capture | Beta |
| --- | --- | --- | --- |
| LLY: Eli Lilly and Company (this page) | 101% | 6.0% | 0.37 |
| VKTX: Viking Therapeutics, Inc. | 164% | 104% | 1.21 |
| BIIB: Biogen Inc. | 35.0% | 91.0% | 0.28 |
| [ABBV](https://easycompare.io/research/abbv): AbbVie Inc. | 92.0% | 57.0% | 0.54 |
| [AMGN](https://easycompare.io/research/amgn): Amgen Inc. | 74.0% | 64.0% | 0.54 |
| [MRK](https://easycompare.io/research/mrk): Merck & Co., Inc. | 64.0% | 46.0% | 0.30 |
| DXCM: DexCom, Inc. | 97.0% | 97.0% | 1.13 |
| [GILD](https://easycompare.io/research/gild): Gilead Sciences, Inc. | 52.0% | 36.0% | 0.35 |
| [PFE](https://easycompare.io/research/pfe): Pfizer Inc. | 52.0% | 81.0% | 0.54 |
| [TAK](https://easycompare.io/research/tak): Takeda Pharmaceutical Company Limited | 34.0% | 58.0% | 0.44 |
| VTRS: Viatris Inc. | 74.0% | 179% | 1.14 |
| WST: West Pharmaceutical Services, Inc. | 107% | 99.0% | 1.08 |
| [TMO](https://easycompare.io/research/tmo): Thermo Fisher Scientific Inc. | 104% | 104% | 0.81 |
| [JNJ](https://easycompare.io/research/jnj): Johnson & Johnson | 64.0% | 53.0% | 0.46 |
| [REGN](https://easycompare.io/research/regn): Regeneron Pharmaceuticals, Inc. | 55.0% | 66.0% | 0.19 |
| [VRTX](https://easycompare.io/research/vrtx): Vertex Pharmaceuticals Incorporated | 87.0% | 50.0% | 0.46 |
| [AZN](https://easycompare.io/research/azn): AstraZeneca PLC | 60.0% | 39.0% | 0.39 |
| PODD: Insulet Corp. | 81.0% | 82.0% | 0.92 |
| [NVS](https://easycompare.io/research/nvs): Novartis AG | 69.0% | 64.0% | 0.49 |
| [NVO](https://easycompare.io/research/nvo): Novo Nordisk A/S | 75.0% | 94.0% | 0.60 |
| [GSK](https://easycompare.io/research/gsk): GSK plc | 51.0% | 61.0% | 0.52 |
| [BMY](https://easycompare.io/research/bmy): Bristol-Myers Squibb Company | 55.0% | 75.0% | 0.41 |
| [SNY](https://easycompare.io/research/sny): Sanofi | 53.0% | 74.0% | 0.46 |

### What diversifies LLY?

Correlation measures how closely two investments move together, on a scale from 1 (in lockstep) through 0 (unrelated) to -1 (in opposite directions).

- Moving a fifth of the money in LLY into MPC would have cut the portfolio's volatility by 20% over the past 5 years and raised its annual return (+39.3% for LLY alone, +43.5% for the mix).
- Among large ETFs, LVHI, DXJ and EMLP have moved largely independently of LLY over the past 5 years, with correlations of 0.23 or lower, and each still earned a positive 5-year return.
- FIX made money in five of the eight calendar years in which LLY lost money.

| Investment | Correlation with LLY | 5Y return | Volatility | Sharpe | Rose in LLY's 8 down years |
| --- | --- | --- | --- | --- | --- |
| LVHI: Franklin International Low Volatility High Dividend Index ETF | 0.02 | +119% | 11.1% | 1.48 | 0 of 8 |
| DXJ: WisdomTree Japan Hedged Equity Fund | 0.23 | +225% | 19.1% | 1.34 | 2 of 8 |
| EMLP: First Trust North American Energy Infrastructure Fund | 0.04 | +101% | 14.5% | 1.04 | 1 of 8 |
| HDV: iShares Core High Dividend ETF | 0.15 | +83.3% | 13.0% | 1.00 | 1 of 8 |
| [SMH](https://easycompare.io/research/smh): VanEck Semiconductor ETF | 0.16 | +323% | 36.9% | 0.97 | 2 of 8 |
| DBEF: Xtrackers MSCI EAFE Hedged Equity ETF | 0.22 | +85.0% | 13.8% | 0.96 | 1 of 8 |
| [GLD](https://easycompare.io/research/gld): SPDR Gold Shares | 0.02 | +126% | 18.9% | 0.96 | 4 of 8 |
| SPMO: Invesco S&P 500 Momentum ETF | 0.33 | +136% | 20.8% | 0.93 | 1 of 8 |

## Common questions

### What was LLY's worst drawdown?

LLY's deepest decline since it began trading in 1986 was 68.3%, from August 2000 to March 2009. It took about six years from the low to climb back to its old high.

### What were LLY's best and worst years?

Over 29 full calendar years, LLY's best year was 1997, when it returned 93.6%. Its worst was 1999, with a return of -24.3%.

### Is there a better investment than LLY?

Looking beyond its popular alternatives, CAH (health care distribution) earned more than LLY with less volatility over the past 5 years: 42.1% a year at 24.7% volatility, against 40.7% a year at 32.8%. Few investments have done better on both counts: only one of the 3,633 stocks and funds worth at least $500 million earned more than LLY with less volatility over the past 5 years, among them CAH.

### Is LLY more volatile than the S&P 500?

Yes. LLY's volatility over the past 5 years was 32.8%, about twice the S&P 500's 17.1%. Volatility measures how widely returns swing around their average: in roughly two years out of three, LLY's return lands within 32.8% of its average, either way. The higher it is, the rougher the ride and the harder it is to hold through a slump.

### What is LLY's Sharpe ratio?

LLY's Sharpe ratio over the past 5 years was 1.21, against 0.79 for the S&P 500, so LLY earned more for each unit of risk than an index fund did. The Sharpe ratio is the return earned above cash for each unit of volatility: two investments with the same return are not equal if one got there with far bigger swings.

### How correlated is LLY with the S&P 500?

Over the past 5 years, LLY's monthly returns had a correlation of 0.22 with the S&P 500. Correlation runs from 1 (moving in lockstep) through 0 (unrelated) to −1 (moving in opposite directions). They are only loosely linked, which makes it a real diversifier next to an index fund. In the table, the correlation column measures each option against LLY instead: the lower it is, the more that option would diversify a LLY holding.

### What are the best alternatives to LLY?

None of the 22 popular alternatives we compared outperformed LLY in at least 3 of 5 short-term and 2 of 3 long-term timeframes, which says more about LLY's strength than about its alternatives.

### Did LLY outperform the S&P 500?

LLY finished ahead of the S&P 500 (SPY) in 16 of 29 full calendar years. In 2025, it returned +40.2%, against +17.7% for the index.

### How did LLY do in stock market crashes?

LLY fell less than the S&P 500 (SPY) in seven of the ten major crashes it has traded through, and further in three. The clearest case was the Covid crash, when LLY fell 16.9% and the S&P 500 fell 33.7%.

### What diversifies LLY?

These had a low correlation with LLY over the past 5 years and still earned a positive 5-year return: among large ETFs, LVHI (correlation 0.02), DXJ (correlation 0.23) and EMLP (correlation 0.04); among large stocks, CAH (correlation 0.28), CLS (correlation -0.04) and FIX (correlation 0.08). A correlation near zero means the two have moved largely independently.

## More research

- [AbbVie (ABBV) Performance, Alternatives and Market Rank](https://easycompare.io/research/abbv)
- [Amgen (AMGN) Performance, Alternatives and Market Rank](https://easycompare.io/research/amgn)
- [Merck & Co., Inc. (MRK) Performance, Alternatives and Market Rank](https://easycompare.io/research/mrk)
- [Gilead Sciences (GILD) Performance, Alternatives and Market Rank](https://easycompare.io/research/gild)
- [Pfizer (PFE) Performance, Alternatives and Market Rank](https://easycompare.io/research/pfe)
- [Takeda Pharmaceutical (TAK) Performance, Alternatives and Market Rank](https://easycompare.io/research/tak)
- [Thermo Fisher Scientific (TMO) Performance, Alternatives and Market Rank](https://easycompare.io/research/tmo)
- [Johnson & Johnson (JNJ) Performance, Alternatives and Market Rank](https://easycompare.io/research/jnj)
- [Regeneron Pharmaceuticals (REGN) Performance, Alternatives and Market Rank](https://easycompare.io/research/regn)
- [Vertex Pharmaceuticals (VRTX) Performance, Alternatives and Market Rank](https://easycompare.io/research/vrtx)
- [AstraZeneca (AZN) Performance, Alternatives and Market Rank](https://easycompare.io/research/azn)
- [Novartis (NVS) Performance, Alternatives and Market Rank](https://easycompare.io/research/nvs)

## Explore further

- Full page with charts: https://easycompare.io/research/lly
- All research pages: https://easycompare.io/llms.txt
- Compare the entire market against LLY live: https://betterthanspy.com/?b=LLY&utm_source=easycompare&utm_medium=research